Experienced pharmaceutical injury lawyers Golomb & Honik have brought lawsuits on behalf of people injured from levetiracetam use. Call our office at 215 985-9177 to speak to an attorney who is an expert in this field. We will provide you with a knowledgeable and in-depth evaluation of your case, at no charge.
Levetiracetam is the generic name of a “second generation” antiepileptic drug (AED) used to treat seizures in patients with epilepsy, head injury or other neurological impairments. Levetiracetam is available by tablet or injection (IV). The drug’s brand-name is Keppra.
In the United States, levetiracetam is approved as adjunctive therapy only (1) for patients 4 and older adults with epilepsy, (2) for patients 12 and older to treat of myoclonic seizures, and (3) for patients 6 and older in the treatment of primary generalized tonic-clonic seizures.
Levetiracetam has been associated with an increased risk of sleepiness, loss of strength or energy, infection and dizziness. Patients have also reported changes in behavior, personality, and mood, including problems walking and moving, increased incidences of psychotic symptoms such as hallucinations, delusions and/or paranoia, and feelings of confusion, hostility and aggression. The most common side effects for children on levetiracetam include accidental injury, irritability, and hostility.
Patients that switch from anticonvulsant Keppra© tablets to levetiracetam tablets report adverse events following the switch, including breakthrough seizures, increased number of seizures and seizures lasting longer in duration. These patients also report marked increases in side effects, including increased and significant drowsiness and changes in behavior, personality, and mood.
Despite evidence of these issues from 2006, generic manufacturers continue to offer generic levetiracetam tablets to patients on Keppra, knowing full well that many insurance plans and other third party payors will automatically switch patients from the branded medicine Keppra to the generic product levetiracetam.
As a result of this involuntary switch, patients have suffered while generic drug manufacturers have reaped millions of dollars in profit.
Golomb & Honik is prepared to take action. The firm is seeking out patients like you that were switched from Keppra to levetiracetam. We want to hear your story. Whether you or someone you love has suffered from increased or breakthrough seizures, worsening side effects or even just a lack of control over your symptoms following the generic substitution, we may be able to help.
Experienced pharmaceutical injury lawyers Golomb & Honik have brought lawsuits on behalf of people injured from levetiracetam use. Call our office at 215 985-9177 to speak to an attorney who is an expert in this field. We will provide you with a knowledgeable and in-depth evaluation of your case, at no charge. |
